High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors

One of the strategies used by tumors to evade immunosurveillance is the accumulation of extracellular adenosine, which has immunosupressive and tumor promoting effects. The study of the mechanisms leading to adenosine formation at the tumor interstitium are therefore of great interest in oncology. T...

ver descrição completa

Detalhes bibliográficos
Autores: Aliagas Marín, Elisabeth, Vidal-Bel, August, Texidó, Laura, Ponce i Sebastià, Jordi, Condom i Mundó, Enric, Martín Satué, Mireia
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2014
País:España
Recursos:Universidad de Barcelona
Repositório:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/68311
Acesso em linha:https://hdl.handle.net/2445/68311
Access Level:Acceso aberto
Palavra-chave:Càncer d'endometri
Enzims
Endometrial cancer
Enzymes
id ES_183e433e8df0ee6a4a70dd44cc640ab6
oai_identifier_str oai:diposit.ub.edu:2445/68311
network_acronym_str ES
network_name_str España
repository_id_str
spelling High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumorsAliagas Marín, ElisabethVidal-Bel, AugustTexidó, LauraPonce i Sebastià, JordiCondom i Mundó, EnricMartín Satué, MireiaCàncer d'endometriEnzimsEndometrial cancerEnzymesOne of the strategies used by tumors to evade immunosurveillance is the accumulation of extracellular adenosine, which has immunosupressive and tumor promoting effects. The study of the mechanisms leading to adenosine formation at the tumor interstitium are therefore of great interest in oncology. The dominant pathway generating extracellular adenosine in tumors is the dephosphorylation of ATP by ecto-nucleotidases. Two of these enzymes acting sequentially, CD39 and CD73, efficiently hydrolyze extracellular ATP to adenosine. They have been found to play a crucial role in a variety of tumors, but there were no data concerning endometrial cancer, the most frequent of the invasive tumors of the female genital tract. The aim of the present work is to study the expression of CD39 and CD73 in human endometrial cancer. We have analyzed protein and gene expression, as well as enzyme activity, in type I endometrioid adenocarcinomas and type II serous adenocarcinomas and their nonpathological endometrial counterparts. High levels of both enzymes were found in tumor samples, with significantly increased expression of CD39 in type II serous tumors, which also coincided with the higher tumor grade. Our results reinforce the involvement of the adenosinergic system in cancer, emphasizing the relevance of ecto-nucleotidases as emerging therapeutic targets in oncology.Hindawi Publishing Corporation2014info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/68311Articles publicats en revistes (Patologia i Terapèutica Experimental)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: http://dx.doi.org/10.1155/2014/509027Mediators of Inflammation, 2014, vol. 2014, p. 1-8http://dx.doi.org/10.1155/2014/509027cc-by (c) Aliagas Marín, Elisabeth et al., 2014http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/683112026-05-27T06:46:51Z
dc.title.none.fl_str_mv High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors
title High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors
spellingShingle High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors
Aliagas Marín, Elisabeth
Càncer d'endometri
Enzims
Endometrial cancer
Enzymes
title_short High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors
title_full High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors
title_fullStr High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors
title_full_unstemmed High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors
title_sort High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors
dc.creator.none.fl_str_mv Aliagas Marín, Elisabeth
Vidal-Bel, August
Texidó, Laura
Ponce i Sebastià, Jordi
Condom i Mundó, Enric
Martín Satué, Mireia
author Aliagas Marín, Elisabeth
author_facet Aliagas Marín, Elisabeth
Vidal-Bel, August
Texidó, Laura
Ponce i Sebastià, Jordi
Condom i Mundó, Enric
Martín Satué, Mireia
author_role author
author2 Vidal-Bel, August
Texidó, Laura
Ponce i Sebastià, Jordi
Condom i Mundó, Enric
Martín Satué, Mireia
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Càncer d'endometri
Enzims
Endometrial cancer
Enzymes
topic Càncer d'endometri
Enzims
Endometrial cancer
Enzymes
description One of the strategies used by tumors to evade immunosurveillance is the accumulation of extracellular adenosine, which has immunosupressive and tumor promoting effects. The study of the mechanisms leading to adenosine formation at the tumor interstitium are therefore of great interest in oncology. The dominant pathway generating extracellular adenosine in tumors is the dephosphorylation of ATP by ecto-nucleotidases. Two of these enzymes acting sequentially, CD39 and CD73, efficiently hydrolyze extracellular ATP to adenosine. They have been found to play a crucial role in a variety of tumors, but there were no data concerning endometrial cancer, the most frequent of the invasive tumors of the female genital tract. The aim of the present work is to study the expression of CD39 and CD73 in human endometrial cancer. We have analyzed protein and gene expression, as well as enzyme activity, in type I endometrioid adenocarcinomas and type II serous adenocarcinomas and their nonpathological endometrial counterparts. High levels of both enzymes were found in tumor samples, with significantly increased expression of CD39 in type II serous tumors, which also coincided with the higher tumor grade. Our results reinforce the involvement of the adenosinergic system in cancer, emphasizing the relevance of ecto-nucleotidases as emerging therapeutic targets in oncology.
publishDate 2014
dc.date.none.fl_str_mv 2014
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/68311
url https://hdl.handle.net/2445/68311
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: http://dx.doi.org/10.1155/2014/509027
Mediators of Inflammation, 2014, vol. 2014, p. 1-8
http://dx.doi.org/10.1155/2014/509027
dc.rights.none.fl_str_mv cc-by (c) Aliagas Marín, Elisabeth et al., 2014
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Aliagas Marín, Elisabeth et al., 2014
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.source.none.fl_str_mv Articles publicats en revistes (Patologia i Terapèutica Experimental)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403973629247488
score 15.198674

Registros relacionados